Case number 2020-1747
Teva Pharmaceuticals v. Eli Lilly and Company > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Oct 7, 2021 | 81 | Mandate issued to the United States Patent and Trademark Office. Service as of this date by the Clerk of Court. [804291] [20-1747, 20-1748, 20-1750] [MVH] [Entered: 10/07/2021 12:31 PM] (2) |
| Aug 22, 2021 | 0 | TEVA PHARMACEUTICALS v. ELI LILLY AND COMPANY [OPINION] [precedential] (0) |
| Aug 16, 2021 | 80 | JUDGMENT. AFFIRMED. Terminated on the merits after oral argument. COSTS: Costs taxed against Appellant(s). Mandate to issue in due course. For information regarding costs, petitions for rehearing, and petitions for writs of certiorari click here. Service as of this date by the Clerk of Court. [792760] [20-1747, 20-1748, 20-1750] [MVH] [Entered: 08/16/2021 09:44 AM] (1) |
| Aug 16, 2021 | 79 | OPINION filed for the court by Lourie, Circuit Judge; Bryson, Circuit Judge and O'Malley, Circuit Judge. Precedential Opinion. Service as of this date by the Clerk of Court. [792759] [20-1747, 20-1748, 20-1750] [MVH] [Entered: 08/16/2021 09:43 AM] (25) |
| Jul 29, 2021 | 78 | ORDER filed lifting stay. By: Merits Panel (Per Curiam). Service as of this date by the Clerk of Court. [789495] [MVH] [Entered: 07/29/2021 04:57 PM] (2) |
| Jul 28, 2021 | 77 | RESPONSE of Appellant Teva Pharmaceuticals International GmbH to Doc. No. [76], [76]. Service: 07/28/2021 by email. [789201] [20-1747] [William Jay] [Entered: 07/28/2021 03:08 PM] (4) |
| Jul 23, 2021 | 76 | ORDER filed. Within 5 days from the date of this order, Teva Pharmaceuticals International GmbH shall elect one of the two options identified in the order. By: Merits Panel (Per Curiam). Service as of this date by the Clerk of Court. [788377] [MJL] [Entered: 07/23/2021 02:10 PM] (2) |
| Jul 21, 2021 | 74 | MODIFIED ENTRY: RESPONSE of Eli Lilly and Company to Doc. No. [72]. Service: 07/21/2021 by email. [787766]--[Edited 07/22/2021 by MJL to correct filing event] [William Raich] [Entered: 07/21/2021 04:36 PM] (17) |
| Jul 21, 2021 | 75 | RESPONSE of Intervenor Andrew Hirshfeld to Doc. No. [72], [72], [72]. Service: 07/21/2021 by email. [787797] [20-1747] [Monica Lateef] [Entered: 07/21/2021 04:57 PM] (6) |
| Jul 7, 2021 | 73 | MODIFIED ENTRY: RESPONSE of Teva Pharmaceuticals International GmbH to Doc. No. [72]. Service: 07/07/2021 by email. [784616]--[Edited 07/08/2021 by MJL to correct filing event] [William Jay] [Entered: 07/07/2021 04:18 PM] (18) |
| Jun 23, 2021 | 72 | ORDER filed. Within 14 days from the date of this order, the parties that raised an Appointments Clause challenge shall file a brief, not to exceed 10 pages double-spaced, explaining how they believe their cases should proceed in light of Arthrex. Responses from the other parties, including the United States Patent and Trademark Office, subject to the same length restrictions, are due within 14 days thereafter. All deadlines and proceedings are stayed. Service as of this date by the Clerk of Court. [782106] [20-1587, 20-1588, 20-1589, 20-1590, 20-1591, 20-1592, 20-1593, 20-1594, 20-1654, 20-1747, 20-1748, 20-1749, 20-1750, 20-1751, 20-1752, 20-1871, 20-2029, 20-2032, 20-2033, 20-2034, 20-2159] [MJL] [Entered: 06/23/2021 04:58 PM] (2) |
| Jun 7, 2021 | 71 | Submitted after ORAL ARGUMENT to Panel: Lourie, Circuit Judge; Bryson, Circuit Judge and O'Malley, Circuit Judge.Arguing counsel: Mr. William M. Jay for Teva Pharmaceuticals International GmbH and William Barrett Raich for Eli Lilly and Company.Oral Argument Audio available here. [778778] [JCP] [Entered: 06/07/2021 01:30 PM] (0) |
| Jun 2, 2021 | 70 | MODIFIED ENTRY: CORRECTED APPENDIX FILED by Teva Pharmaceuticals International GmbH. Service: 06/02/2021 by email. [778212]--[Edited 06/03/2021 by MJL - compliance review complete] [William Jay] [Entered: 06/02/2021 05:35 PM] (1897) |
| Jun 2, 2021 | 69 | CORRECTED APPENDIX FILED by Appellant Teva Pharmaceuticals International GmbH. Service: 06/02/2021 by email. [778047] [20-1747]. This appendix has been corrected. See Doc. No. [70]. [William Jay] [Entered: 06/02/2021 10:11 AM] (778) |
| Jun 2, 2021 | 68 | Notice of Correction to Doc No. [52] for Appellant Teva Pharmaceuticals International GmbH. Service: 06/02/2021 by email. [778038] [20-1747] [William Jay] [Entered: 06/02/2021 10:05 AM] (4) |
| May 17, 2021 | 67 | Response to notice of oral argument from Appellant Teva Pharmaceuticals International GmbH. Service: 05/17/2021 by email. [775367] [20-1747] [William Jay] [Entered: 05/17/2021 12:26 PM] (1) |
| May 17, 2021 | 66 | Response to notice of oral argument from Appellee Eli Lilly and Company. Service: 05/17/2021 by email. [775281] [20-1747] [William Raich] [Entered: 05/17/2021 09:55 AM] (1) |
| May 13, 2021 | 65 | ORDER filed. Appeals 20-1747 and 20-1749 are consolidated for purposes of oral argument. Each side will be allotted 20 minutes of argument time. By: Merits Panel (Per Curiam). Service as of this date by the Clerk of Court. [774901] [20-1747, 20-1749] [MJL] [Entered: 05/13/2021 04:17 PM] (3) |
| Apr 22, 2021 | 64 | Response to notice of oral argument from Intervenor Andrew Hirshfeld. Service: 04/22/2021 by email. [770670] [20-1747] [Monica Lateef] [Entered: 04/22/2021 04:01 PM] (1) |
| Apr 21, 2021 | 63 | NOTICE OF TELEPHONIC ORAL ARGUMENT. Panel: 2106B. Case scheduled June 7, 2021. Response to Notice of Oral Argument due: 05/17/2021. Please review the attached Notice. The response to notice of oral argument form can be found here. The Oral Argument Guide can be found here. The Counsel Telephonic Argument Orientation Information can be found here. Service as of this date by the Clerk of Court. [770321] [JCP] [Entered: 04/21/2021 05:09 PM] (1) |
| Apr 19, 2021 | 60 | The following conflict date submitted by William Barrett Raich for Eli Lilly and Company has been accepted by the court: 08/02/2021. [769634] [MJL] [Entered: 04/19/2021 03:50 PM] (0) |
| Apr 19, 2021 | 59 | Notice from Appellee Eli Lilly and Company regarding conflicts with oral argument. Service: 04/19/2021 by email. [769626] [20-1747] [William Raich] [Entered: 04/19/2021 03:43 PM] (3) |
| Apr 19, 2021 | 58 | Notice from Intervenor Andrew Hirshfeld regarding conflicts with oral argument. None. Service: 04/19/2021 by email. [769525] [20-1747] [Monica Lateef] [Entered: 04/19/2021 11:12 AM] (0) |
| Apr 16, 2021 | 62 | 6 paper copies of Doc. No. [41] received from Intervenor Andrew Hirshfeld. [769915] [VDW] [Entered: 04/20/2021 11:59 AM] (0) |
| Apr 16, 2021 | 61 | 6 paper copies of Doc. No. [52], [46], [44] received from Appellant Teva Pharmaceuticals International GmbH. [769914] [VDW] [Entered: 04/20/2021 11:57 AM] (0) |
| Apr 13, 2021 | 57 | 6 paper copies of Doc. No. [36] received from Appellee Eli Lilly and Company. [769343] [VDW] [Entered: 04/16/2021 02:36 PM] (0) |
| Apr 13, 2021 | 56 | The following conflict dates submitted by William M. Jay for Teva Pharmaceuticals International GmbH have been accepted by the court: 06/09/2021, 06/10/2021, 06/11/2021, 08/06/2021. [768216] [MJL] [Entered: 04/13/2021 10:09 AM] (0) |
| Apr 12, 2021 | 55 | Notice from Appellant Teva Pharmaceuticals International GmbH regarding conflicts with oral argument. Service: 04/12/2021 by email. [768098] [20-1747] [William Jay] [Entered: 04/12/2021 04:20 PM] (2) |
| Apr 12, 2021 | 54 | Notice to counsel: The Clerk's Office directs that outstanding paper copies of all briefs and appendices in this case must be submitted on or before April 19, 2021. See Administrative Order No. 20-01 (Mar. 20, 2020). [767979] [KMH] [Entered: 04/12/2021 11:02 AM] (0) |
| Apr 12, 2021 | 53 | Notice to Advise of Scheduling Conflicts. Arguing counsel must advise of, and show good cause for, any scheduling conflicts during the upcoming court session months listed in the attached notice. The Response to Notice to Advise of Scheduling Conflicts can be found here. The Oral Argument Guide can be found here. [767976] [KMH] [Entered: 04/12/2021 10:57 AM] (1) |
| Feb 12, 2021 | 51 | Notice of Correction to Doc No. [49] for Appellant Teva Pharmaceuticals International GmbH. Service: 02/12/2021 by email. [755904] [20-1747] [William Jay] [Entered: 02/12/2021 03:06 PM] (0) |
| Feb 12, 2021 | 52 | MODIFIED ENTRY: CORRECTED APPENDIX FILED by Appellant Teva Pharmaceuticals International GmbH. Service: 02/12/2021 by email. [755914] --[Edited 02/17/2021 by KMH - compliance review complete] [William Jay] [Entered: 02/12/2021 03:20 PM] (0) |
| Feb 11, 2021 | 50 | Certificate of Compliance with Fed. Cir. R. 25.1(c)(2) for Appellee Eli Lilly and Company. Service: 02/11/2021 by email. [755639] [20-1747] [William Raich] [Entered: 02/11/2021 09:21 PM] (0) |
| Feb 11, 2021 | 49 | APPENDIX FILED by Appellant Teva Pharmaceuticals International GmbH. Service: 02/11/2021 by email. [755633] [20-1747] This document has been corrected. See Doc No. [52] [William Jay] [Entered: 02/11/2021 07:47 PM] (0) |
| Feb 11, 2021 | 48 | Joint Statement of Compliance with Fed. Cir. R. 33 for Appellant Teva Pharmaceuticals International GmbH. Service: 02/11/2021 by email. [755600] [20-1747] [William Jay] [Entered: 02/11/2021 05:02 PM] (0) |
| Feb 11, 2021 | 47 | Certificate of Compliance with Fed. Cir. R. 25.1(c)(2) for Appellant Teva Pharmaceuticals International GmbH. Service: 02/11/2021 by email. [755599] [20-1747] [William Jay] [Entered: 02/11/2021 04:59 PM] (0) |
| Feb 11, 2021 | 46 | MODIFIED ENTRY: CORRECTED BRIEF FILED by Appellant Teva Pharmaceuticals International GmbH. Service: 02/11/2021 by email. [755589]--[Edited 02/17/2021 by KMH - compliance review complete] [William Jay] [Entered: 02/11/2021 04:52 PM] (0) |
| Feb 11, 2021 | 45 | Notice of Correction to Doc No. [26] for Appellant Teva Pharmaceuticals International GmbH. Service: 02/11/2021 by email. [755582] [20-1747] [William Jay] [Entered: 02/11/2021 04:47 PM] (0) |
| Feb 4, 2021 | 44 | MODIFIED ENTRY: REPLY BRIEF FILED by Appellant Teva Pharmaceuticals International GmbH. Service: 02/04/2021 by email. Unless ordered otherwise, any responsive deadline runs from the date of service of this brief. See Fed. Cir. R. 31. [754102] --[Edited 02/08/2021 by KMH - compliance review complete] [William Jay] [Entered: 02/04/2021 07:00 PM] (0) |
| Jan 22, 2021 | 43 | Official caption revised to reflect Andrew Hirshfeld, Performing the Functions and Duties of the Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office, as Intervenor. (see attached). Service as of this date by the Clerk of Court. [751069] [KMH] [Entered: 01/22/2021 02:06 PM] (0) |
| Jan 6, 2021 | 42 | Docketing Statement for the Intervenor Andrei Iancu. Service: 01/06/2021 by email. [747313] [20-1747] [Monica Lateef] [Entered: 01/06/2021 12:00 PM] (2) |
| Dec 29, 2020 | 41 | MODIFIED ENTRY: CORRECTED BRIEF FILED by Intervenor Andrei Iancu. Service: 12/29/2020 by email. [745852] --[Edited 01/05/2021 by KMH - compliance review complete] [Monica Lateef] [Entered: 12/29/2020 03:36 PM] (12) |
| Dec 28, 2020 | 40 | NOTICE OF NON-COMPLIANCE: The submission of Intervenor Andrei Iancu, Intervenor Brief [32], is not in compliance with the rules of this court (see attached). Compliant document due on 01/05/2021. Service as of this date by the Clerk of Court. [745462] [KMH] [Entered: 12/28/2020 02:13 PM] (1) |
| Dec 23, 2020 | 39 | ORDER granting motion to extend time to file brief [37] filed by Appellant Teva Pharmaceuticals International GmbH. in 20-1747, granting motion to extend time to file brief [744399-2] filed by Appellant Teva Pharmaceuticals International GmbH. in 20-1749. The reply brief in each of the above-captioned appeals is due 02/04/2021. Service as of this date by the Clerk of Court. [745160] [20-1747, 20-1749] [LMS] [Entered: 12/23/2020 03:45 PM] (2) |
| Dec 23, 2020 | 38 | ORDER filed granting [31] [740257-2] the Director’s motions. The revised official captions are reflected above. The Director is directed to file a docketing statement in each set of appeals no later than 14 days from the date of filing of this order. Service as of this date by the Clerk of Court. [745155] [20-1747, 20-1749] [LMS] [Entered: 12/23/2020 03:31 PM] (3) |
| Dec 21, 2020 | 37 | MOTION of Appellant Teva Pharmaceuticals International GmbH to extend the time to 02/04/2021 to file brief. Service: 12/21/2020 by email. [744397] [20-1747] [William Jay] [Entered: 12/21/2020 03:21 PM] (9) |
| Dec 15, 2020 | 36 | MODIFIED ENTRY: CORRECTED BRIEF FILED by Appellee Eli Lilly and Company. Service: 12/15/2020 by email. [742952] --[Edited 12/28/2020 by KMH - compliance review complete] [William Raich] [Entered: 12/15/2020 04:20 PM] (80) |
| Dec 10, 2020 | 35 | NOTICE OF NON-COMPLIANCE: The submission of Appellee Eli Lilly and Company, Response Brief [34], is not in compliance with the rules of this court (see attached). Compliant document is due on 12/17/2020. Unless ordered otherwise, the deadline for any responsive filing runs from service of the original version. Service as of this date by the Clerk of Court. [741862] [LMN] [Entered: 12/10/2020 01:27 PM] (1) |
| Dec 4, 2020 | 34 | RESPONSE BRIEF FILED by Appellee Eli Lilly and Company. Service: 12/04/2020 by email. [740329] [20-1747] This document is non-compliant. See Doc No. [35] [William Raich] [Entered: 12/04/2020 12:52 PM] (79) |
| Dec 4, 2020 | 33 | Entry of appearance for Monica B. Lateef; Thomas W. Krause; Farheena Y. Rasheed; Brian Racilla as counsel for Intervenor Andrei Iancu, Director of the United States Patent and Trademark Office. Service: 12/04/2020 by email. [740253] [20-1747] [Monica Lateef] [Entered: 12/04/2020 10:36 AM] (2) |
| Dec 4, 2020 | 31 | Notice of Intervention pursuant to the provisions of 35 USC Section 143 from the Director of the United States Patent and Trademark Office. Service: 12/04/2020 by email. [740246] [20-1747] [Monica Lateef] [Entered: 12/04/2020 10:29 AM] (3) |
| Dec 4, 2020 | 32 | INTERVENOR BRIEF FILED by Andrei Iancu, Director of the United States Patent and Trademark Office. Service: 12/04/2020 by email. This document is non-compliant. See Doc No. [40] [740248] [20-1747] [Monica Lateef] [Entered: 12/04/2020 10:32 AM] (11) |
| Dec 3, 2020 | 30 | Entry of appearance for Charles T. Collins-Chase as counsel for Appellee Eli Lilly and Company. Service: 12/03/2020 by email. [739934] [20-1747] [William Raich] [Entered: 12/03/2020 11:35 AM] (1) |
| Oct 15, 2020 | 29 | **TEXT ONLY** ORDER granting motion to extend time to file brief [28] filed by Appellee Eli Lilly and Company. The response brief is due 12/04/2020. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [729078] [EKD] [Entered: 10/15/2020 02:05 PM] (0) |
| Oct 15, 2020 | 28 | MOTION of Appellee Eli Lilly and Company to extend the time to 12/04/2020 to file brief. Service: 10/15/2020 by email. [728951] [20-1747] [William Raich] [Entered: 10/15/2020 11:50 AM] (9) |
| Oct 15, 2020 | 27 | Amended Certificate of Interest for Appellee Eli Lilly and Company. Service: 10/15/2020 by email. [728946] [20-1747] [William Raich] [Entered: 10/15/2020 11:46 AM] (3) |
| Sep 16, 2020 | 26 | MODIFIED ENTRY: OPENING BRIEF FILED for Appellant Teva Pharmaceuticals International GmbH. Number of Pages: 62. Service: 09/16/2020 by email. Unless ordered otherwise, any responsive deadline runs from the date of service of this brief. See Fed. Cir. R. 31. [722329] --[Edited 09/17/2020 by LMN - compliance review complete] This documetn has been corrected. See Doc No. [46] [William Jay] [Entered: 09/16/2020 09:20 PM] (468) |
| Jul 24, 2020 | 25 | **TEXT ONLY** ORDER granting motion to extend time to file brief [24] filed by Appellant Teva Pharmaceuticals International GmbH. The opening brief is due 09/16/2020. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [709976] [LMN] [Entered: 07/24/2020 01:48 PM] (0) |
| Jul 24, 2020 | 24 | MOTION of Appellant Teva Pharmaceuticals International GmbH to extend the time to 09/16/2020 to file the Appellant's Opening Brief due 08/07/2020. [Consent: unopposed]. Service: 07/24/2020 by email. [709892] [20-1747] [William Jay] [Entered: 07/24/2020 10:51 AM] (9) |
| Jun 25, 2020 | 23 | Entry of appearance for William H. Milliken as of counsel for Appellant Teva Pharmaceuticals International GmbH. Service: 06/25/2020 by email. [703792] [20-1747] [William Milliken] [Entered: 06/25/2020 05:15 PM] (2) |
| Jun 25, 2020 | 22 | Entry of appearance for Deborah Ann Sterling as of counsel for Appellant Teva Pharmaceuticals International GmbH. Service: 06/25/2020 by email. [703786] [20-1747] [Deborah Sterling] [Entered: 06/25/2020 05:11 PM] (2) |
| Jun 10, 2020 | 21 | Certified list received. Service: 06/08/2020 by email. Refer to Fed. Cir. R. 31 for calculating brief deadlines from service of the certified list. [700235] [LMN] [Entered: 06/10/2020 09:02 AM] (622) |
| May 12, 2020 | 19 | Certificate of Interest for Appellant Teva Pharmaceuticals International GmbH. Service: 05/12/2020 by email. [694014] [20-1747] [William Jay] [Entered: 05/12/2020 02:58 PM] (2) |
| May 12, 2020 | 18 | Entry of appearance for Natasha E. Daughtrey as of counsel for Appellant Teva Pharmaceuticals International GmbH. Service: 05/12/2020 by email. [694001] [20-1747] [Natasha Daughtrey] [Entered: 05/12/2020 02:38 PM] (2) |
| May 12, 2020 | 17 | Entry of appearance for Elaine Herrmann Blais as of counsel for Appellant Teva Pharmaceuticals International GmbH. Service: 05/12/2020 by email. [693996] [20-1747] [Elaine Blais] [Entered: 05/12/2020 02:31 PM] (2) |
| May 12, 2020 | 16 | Entry of appearance for Alexandra Lu as of counsel for Appellant Teva Pharmaceuticals International GmbH. Service: 05/12/2020 by email. [693986] [20-1747] [Alexandra Lu] [Entered: 05/12/2020 02:16 PM] (2) |
| May 12, 2020 | 15 | Entry of appearance for William M. Jay as principal counsel for Appellant Teva Pharmaceuticals International GmbH. Service: 05/12/2020 by email. [693977] [20-1747] [William Jay] [Entered: 05/12/2020 02:05 PM] (2) |
| May 12, 2020 | 14 | Entry of appearance for Edwina Clarke as of counsel for Appellant Teva Pharmaceuticals International GmbH. Service: 05/12/2020 by email. [693971] [20-1747] [Edwina Clarke] [Entered: 05/12/2020 01:48 PM] (2) |
| May 12, 2020 | 13 | Docketing Statement for the Appellee Eli Lilly and Company. Service: 05/12/2020 by email. [693834] [20-1747] [William Raich] [Entered: 05/12/2020 10:27 AM] (2) |
| May 12, 2020 | 12 | Certificate of Interest for Appellee Eli Lilly and Company. Service: 05/12/2020 by email. [693833] [20-1747] [William Raich] [Entered: 05/12/2020 10:25 AM] (2) |
| May 12, 2020 | 11 | Entry of appearance for Mark J. Stewart as of counsel for Appellee Eli Lilly and Company. Service: 05/12/2020 by email. [693832] [20-1747] [William Raich] [Entered: 05/12/2020 10:24 AM] (1) |
| May 12, 2020 | 10 | Entry of appearance for Sanjay M. Jivraj as of counsel for Appellee Eli Lilly and Company. Service: 05/12/2020 by email. [693828] [20-1747] [William Raich] [Entered: 05/12/2020 10:22 AM] (1) |
| May 12, 2020 | 9 | Entry of appearance for Pier D. DeRoo as of counsel for Appellee Eli Lilly and Company. Service: 05/12/2020 by email. [693823] [20-1747] [William Raich] [Entered: 05/12/2020 10:15 AM] (1) |
| May 12, 2020 | 8 | Entry of appearance for Pier D. DeRoo as of counsel for Appellee Eli Lilly and Company. Service: 05/12/2020 by email. [693819] [20-1747] [William Raich] [Entered: 05/12/2020 10:12 AM] (1) |
| May 12, 2020 | 7 | Entry of appearance for Yieyie Yang as of counsel for Appellee Eli Lilly and Company. Service: 05/12/2020 by email. [693810] [20-1747] [William Raich] [Entered: 05/12/2020 10:04 AM] (1) |
| May 12, 2020 | 6 | Entry of appearance for Erin M. Sommers as of counsel for Appellee Eli Lilly and Company. Service: 05/12/2020 by email. [693804] [20-1747] [William Raich] [Entered: 05/12/2020 09:57 AM] (1) |
| May 12, 2020 | 5 | Entry of appearance for William B. Raich as principal counsel for Appellee Eli Lilly and Company. Service: 05/12/2020 by email. [693800] [20-1747] [William Raich] [Entered: 05/12/2020 09:53 AM] (1) |
| May 12, 2020 | 20 | Docketing Statement for the Appellant Teva Pharmaceuticals International GmbH. Service: 05/12/2020 by email. [694018] [20-1747] [William Jay] [Entered: 05/12/2020 03:06 PM] (5) |
| May 1, 2020 | 4 | Note to File: The following cases shall be considered companion cases and assigned to the same merits panel: 20-1747, 20-1748, and 20-1750 with 20-1749, 20-1751, and 20-1752. [691656] [20-1747, 20-1749, 20-1751, 20-1752] [LMN] [Entered: 05/01/2020 01:56 PM] (0) |
| May 1, 2020 | 3 | Note to File: The following cases are consolidated: 20-1747 Lead with 20-1748 and 20-1750 Member Cases. The parties must file all documents in the lead appeal only. [691597] [20-1747, 20-1748, 20-1750] [LMN] [Entered: 05/01/2020 10:59 AM] (0) |
| May 1, 2020 | 2 | ORDER consolidating appeals (20-1747 with 20-1748 and 20-1750). The Certified Lists are due no later than June 8, 2020. Service as of this date by the Clerk of Court. [691596] [20-1747, 20-1748, 20-1750] [LMN] [Entered: 05/01/2020 10:58 AM] (2) |
| Apr 28, 2020 | 1 | Appeal docketed. Received: 04/21/2020. [690464] Entry of Appearance is due 05/12/2020. Certificate of Interest is due on 05/12/2020. Docketing Statement is due 05/12/2020. Certified List is due on 06/08/2020. [LMN] [Entered: 04/28/2020 10:38 AM] (180) |
